Remote clinical trial monitoring uptake rises but validation questions swirl
Need to Know: Wearables can be a value-added aspect to data collection in clinical trials, to complement electronic Patient Reported…
All articles by Jennifer Smith-Parker
Jennifer Smith-Parker
Jennifer C. Smith is an award-winning healthcare editor with 15+ years of expertise in the US and European pharmaceutical, regulatory and pricing/reimbursement sector. She carries in-depth knowledge on the clinical trials landscape and concerns that affect the pharma and biotech industry. She has moderated a number of conferences over the years, and led panel discussions on a wide-ranging set of topics. She has honed her skillet on the intersection of online journalism and business acumen, with a good understanding of SEO concepts and readership analytics to drive content strategy.
-
-
ESG in clinical trials: what pharma needs to know
Rather than just a buzzword, the environmental, social and governance (ESG) framework that defines and manages sustainability risks is very…
-
LoA Update: TG’s Phase III ublituximab for relapsing multiple sclerosis sees 10-point boost to FDA regulatory potential
As of 21 December, the likelihood of approval (LoA) for TG Therapeutics’ Phase III anti-CD20 monoclonal antibody for relapsing multiple sclerosis (RMS)…
-
LoA Update: BeiGene’s Phase III tislelizumab for esophageal squamous cell carcinoma sees 10-point jump for FDA approval forecast
As of 29 January, the US likelihood of approval (LoA) for BeiGene’s Phase III anti-PD-1 antibody for esophageal squamous cell carcinoma (ESCC)…
-
LoA Update: Agios’ Phase III mitapivat sulphate for pyruvate kinase deficiency sees 12-point rise in US approval prospects
As of 28 January, the likelihood of approval (LoA) by the FDA for Agios Pharmaceuticals’ Phase III drug for pyruvate kinase (PK)…
